Expression of DNA Damage Response Molecules PARP1, γH2AX, BRCA1, and BRCA2 Predicts Poor Survival of Breast Carcinoma Patients

被引:20
|
作者
Park, See-Hyoung [1 ]
Noh, Sang Jae [2 ,3 ]
Kim, Kyoung Min [2 ,3 ]
Bae, Jun Sang [2 ,3 ]
Kwon, Keun Sang [3 ,4 ]
Jung, Sung Hoo [3 ,5 ]
Kim, Jung Ryul [3 ,6 ]
Lee, Ho [3 ,7 ]
Chung, Myoung Ja [2 ,3 ]
Moon, Woo Sung [2 ,3 ]
Kang, Myoung Jae [2 ,3 ]
Jang, Kyu Yun [2 ,3 ]
机构
[1] Stanford Univ, Div Gynecol Oncol, Dept Obstet & Gynecol, Sch Med, Stanford, CA 94305 USA
[2] Chonbuk Natl Univ, Sch Med, Dept Pathol, Res Inst Clin Med,Chonbuk Natl Univ Hosp,Biomed R, Jeonju 561180, South Korea
[3] Res Inst Endocrine Sci, Jeonju, South Korea
[4] Chonbuk Natl Univ, Sch Med, Dept Prevent Med, Res Inst Clin Med,Chonbuk Natl Univ Hosp,Biomed R, Jeonju 561180, South Korea
[5] Chonbuk Natl Univ, Sch Med, Dept Surg, Res Inst Clin Med,Chonbuk Natl Univ Hosp,Biomed R, Jeonju 561180, South Korea
[6] Chonbuk Natl Univ, Sch Med, Dept Orthopaed Surg, Res Inst Clin Med,Chonbuk Natl Univ Hosp,Biomed R, Jeonju 561180, South Korea
[7] Chonbuk Natl Univ, Sch Med, Dept Forens Med, Res Inst Clin Med,Chonbuk Natl Univ Hosp,Biomed R, Jeonju 561180, South Korea
来源
TRANSLATIONAL ONCOLOGY | 2015年 / 8卷 / 04期
基金
新加坡国家研究基金会;
关键词
OVARIAN-CARCINOMA; GROWTH-FACTOR; CANCER; PROGNOSIS; REPAIR; ASSOCIATION; MUTATIONS;
D O I
10.1016/j.tranon.2015.04.004
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND: Poly(ADP-ribose) polymerase 1 (PARP1), gamma H2AX, BRCA1, and BRCA2 are conventional molecular indicators of DNA damage in cells and are often overexpressed in various cancers. In this study, we aimed, using immunohistochemical detection, whether the co-expression of PARP1, gamma H2AX, BRCA1, and BRCA2 in breast carcinoma (BCA) tissue can provide more reliable prediction of survival of BCA patients. MATERIALS AND METHODS: We investigated immunohistochemical expression and prognostic significance of the expression of PARP1, gamma H2AX, BRCA1, and BRCA2 in 192 cases of BCAs. RESULTS: The expression of these four molecules predicted earlier distant metastatic relapse, shorter overall survival (OS), and relapse-free survival (RFS) by univariate analysis. Multivariate analysis revealed the expression of PARP1, gamma H2AX, and BRCA2 as independent poor prognostic indicators of OS and RFS. In addition, the combined expressional pattern of BRCA1, BRCA2, PARP1, and gamma H2AX (CSbbph) was an additional independent prognostic predictor for OS (P < .001) and RFS (P < .001). The 10-year OS rate was 95% in the CSbbph-low (CSbbph scores 0 and 1) subgroup, but that was only 35% in the CSbbph-high (CSbbph score 4) subgroup. CONCLUSION: This study has demonstrated that the individual and combined expression patterns of PARP1, gamma H2AX, BRCA1, and BRCA2 could be helpful in determining an accurate prognosis for BCA patients and for the selection of BCA patients who could potentially benefit from anti-PARP1 therapy with a combination of genotoxic chemotherapeutic agents.
引用
收藏
页码:239 / 249
页数:11
相关论文
共 50 条
  • [1] Individual and Combined Expression of DNA Damage Response Molecules PARP1, γH2AX, BRCA1, and BRCA2 Predict Shorter Survival of Soft Tissue Sarcoma Patients
    Kim, Kyoung Min
    Moon, Young Jae
    Park, See-Hyoung
    Park, Hye Jeong
    Wang, Sung Il
    Park, Ho Sung
    Lee, Ho
    Kwon, Keun Sang
    Moon, Woo Sung
    Lee, Dong Geun
    Kim, Jung Ryul
    Jang, Kyu Yun
    PLOS ONE, 2016, 11 (09):
  • [2] BRCA1 and BRCA2 mutations in patients with familial breast cancer
    Bolufer, P
    Munárriz, B
    Santaballa, A
    Velasco, E
    Lerma, E
    Barragán, E
    MEDICINA CLINICA, 2005, 124 (01): : 10 - 12
  • [3] The BRCA1 and BRCA2 Genes in Early-Onset Breast Cancer Patients
    Saleem, Mohamed
    Ghazali, Mohd Bazli
    Wahab, Md Azlan Mohamed Abdul
    Yusoff, Narazah Mohd
    Mahsin, Hakimah
    Seng, Ch'ng Ewe
    Khalid, Imran Abdul
    Rahman, Mohd Nor Gohar
    Yahaya, Badrul Hisham
    CANCER BIOLOGY AND ADVANCES IN TREATMENT, 2020, 1292 : 1 - 12
  • [4] Response to radiation therapy and prognosis in breast cancer patients with BRCA1 and BRCA2 mutations
    Gaffney, DK
    Brohet, RM
    Lewis, CM
    Holden, JA
    Buys, SS
    Neuhausen, SL
    Steele, L
    Avizonis, V
    Stewart, JR
    Cannon-Albright, LA
    RADIOTHERAPY AND ONCOLOGY, 1998, 47 (02) : 129 - 136
  • [5] Faulty BRCA1, BRCA2 genes: how poor is the prognosis?
    O'Quigley, John
    ANNALS OF EPIDEMIOLOGY, 2017, 27 (10) : 672 - 676
  • [6] The Evolution, Functions and Applications of the Breast Cancer Genes BRCA1 and BRCA2
    Pfeffer, Claire M.
    Ho, Benjamin N.
    Singh, Amareshwar T. K.
    CANCER GENOMICS & PROTEOMICS, 2017, 14 (05) : 293 - 298
  • [7] Expression of BRCA1 and BRCA2 proteins and their correlation with clinical staging in breast cancer
    Hedau, Suresh
    Batra, Madhu
    Singh, Usha Rani
    Bharti, Alok C.
    Ray, Amitabha
    Das, Bhudev C.
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2015, 11 (01) : 158 - 163
  • [8] Development of the PARP inhibitor talazoparib for the treatment of advanced BRCA1 and BRCA2 mutated breast cancer
    Hobbs, Evthokia A.
    Litton, Jennifer K.
    Yap, Timothy A.
    EXPERT OPINION ON PHARMACOTHERAPY, 2021, 22 (14) : 1825 - 1837
  • [9] BRCA1 and BRCA2 mutations in Belgian families with a history of breast and/or ovarian
    Sibille-Hoang, C
    Froment, O
    de ter Beerst, AJ
    Lepiece, V
    Huberlant, G
    Blauwaert, G
    Vindevoghel, A
    Canon, JL
    Gillerot, Y
    EUROPEAN JOURNAL OF CANCER PREVENTION, 1998, 7 : S3 - S5
  • [10] Comprehensive genomic characterization of breast tumors with BRCA1 and BRCA2 mutations
    Lal, Avantika
    Ramazzotti, Daniele
    Weng, Ziming
    Liu, Keli
    Ford, James M.
    Sidow, Arend
    BMC MEDICAL GENOMICS, 2019, 12 (1)